TY - JOUR
T1 - Prognostic value of preoperative peripheral monocyte count in patients with hepatocellular carcinoma after liver transplantation
AU - Ren, Qing Qi
AU - Fu, Shun Jun
AU - Zhao, Qiang
AU - Guo, Zhi Yong
AU - Ji, Fei
AU - Chen, Mao Gen
AU - Wu, Lin Wei
AU - He, Xiao Shun
N1 - Funding Information:
This study was supported by the National High Technology Research and Development Program of China (863 Program) (2012AA021007 and 2012AA021008), the Key Clinical Project from the Ministry of Health (2010159), the National Natural Science Foundation of China (81373156 and 81471583), the Special Fund for Science Research by Ministry of Health (201302009), and the Guangdong Provincial Key Laboratory Construction Projection on Organ Donation and Transplant Immunology (2013A061401007). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2016, International Society of Oncology and BioMarkers (ISOBM).
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Prognostic value of peripheral monocyte, as a member of inflammatory cells, was widely being investigated. The aim of this study was to evaluate the prognostic value of preoperative peripheral blood monocyte count for hepatocellular carcinoma (HCC) patients who underwent liver transplantation (LT) and the relationship between monocyte count and tumor-related characteristics. We retrospectively analyzed the clinical data of 101 HCC patients after LT. Preoperative monocyte count and demographic, clinical, and pathologic data were analyzed. The optimal cutoff value of monocyte count was 456/mm3, with the sensitivity and specificity of 69.4 and 61.5 %, respectively. Elevated preoperative peripheral blood monocyte count was significantly associated with large tumor size. The 1-, 3-, and 5-year disease-free survival (DFS) (80.9, 70.1, and 53.3 % vs 55.1, 38.7, and 38.7 %, P = 0.007) and overall survival (OS) rates (95.7, 76.6, and 64.8 % vs 72.2, 44.1, and 36.1 %, P = 0.002) of HCC patients in the peripheral blood monocyte count ≤456/mm3 group were higher than those in the peripheral blood monocyte count >456/mm3 group. In conclusion, elevated preoperative peripheral blood monocyte count was significantly associated with advanced tumor stage and it can be considered as a prognostic factor for HCC patients after LT.
AB - Prognostic value of peripheral monocyte, as a member of inflammatory cells, was widely being investigated. The aim of this study was to evaluate the prognostic value of preoperative peripheral blood monocyte count for hepatocellular carcinoma (HCC) patients who underwent liver transplantation (LT) and the relationship between monocyte count and tumor-related characteristics. We retrospectively analyzed the clinical data of 101 HCC patients after LT. Preoperative monocyte count and demographic, clinical, and pathologic data were analyzed. The optimal cutoff value of monocyte count was 456/mm3, with the sensitivity and specificity of 69.4 and 61.5 %, respectively. Elevated preoperative peripheral blood monocyte count was significantly associated with large tumor size. The 1-, 3-, and 5-year disease-free survival (DFS) (80.9, 70.1, and 53.3 % vs 55.1, 38.7, and 38.7 %, P = 0.007) and overall survival (OS) rates (95.7, 76.6, and 64.8 % vs 72.2, 44.1, and 36.1 %, P = 0.002) of HCC patients in the peripheral blood monocyte count ≤456/mm3 group were higher than those in the peripheral blood monocyte count >456/mm3 group. In conclusion, elevated preoperative peripheral blood monocyte count was significantly associated with advanced tumor stage and it can be considered as a prognostic factor for HCC patients after LT.
KW - Hepatocellular carcinoma
KW - Liver transplantation
KW - Peripheral blood monocyte count
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=84954101077&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84954101077&partnerID=8YFLogxK
U2 - 10.1007/s13277-015-4758-3
DO - 10.1007/s13277-015-4758-3
M3 - Article
C2 - 26753965
AN - SCOPUS:84954101077
VL - 37
SP - 8973
EP - 8978
JO - Tumor Biology
JF - Tumor Biology
SN - 1010-4283
IS - 7
ER -